ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Montréal, QC, CAN:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Montreal, Quebec, Canada and 73 other locations

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

Montreal, Quebec, Canada and 161 other locations

(IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with m ...

Enrolling
Multiple Sclerosis
Drug: RO7121932 - MAD
Drug: RO7121932 SC - SAD

Phase 1

Roche
Roche

Montreal, Quebec, Canada and 23 other locations

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Drug: Disease modifying treatment (DMT)
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Granby, Quebec, Canada and 33 other locations

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Remibrutinib
Drug: Teriflunomide

Phase 3

Novartis
Novartis

Montreal, Quebec, Canada and 229 other locations

for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS...

Active, not recruiting
Multiple Sclerosis
Drug: RPC-1063

Phase 3

Celgene
Celgene

Montreal, Quebec, Canada and 60 other locations

Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple...

Active, not recruiting
Multiple Sclerosis
Drug: Placebo matching IMU-838
Drug: IMU-838

Phase 2

Immunic Therapeutics

Montréal, Canada and 72 other locations

Primary Objective:To determine the long-term safety and tolerability of SAR442168 in RMS participantsSecondary Objective:To evaluate efficacy of SAR4...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Tolebrutinib

Phase 2

Sanofi
Sanofi

Greenfield Park, Canada and 36 other locations

The primary purpose of this study is to evaluate the safety and tolerability of VRG50635 in participants with ALS.

Enrolling
Amyotrophic Lateral Sclerosis
Drug: VRG50635

Phase 1

Verge Genomics

Montreal, Quebec, Canada and 1 other location

Locations recently updated

in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People ...

Enrolling
Multiple Sclerosis
Drug: Activated charcoal
Drug: Cholestyramine

Phase 3

Sanofi
Sanofi

Granby, Quebec, Canada and 69 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems